ESPR

Esperion Therapeutics Inc

Add to Watchlist

Advanced Chart

1.510

+0.02(1.342%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.579

Open

1.500

VWAP

Vol

5.17M

Mkt Cap

299.28M

Low

1.4511

Amount

EV/EBITDA(TTM)

Total Shares

189.46M

477.64M

EV/OCF(TTM)

P/S(TTM)

1.13

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

129.89M

+87.94%

0.060

-159.23%

93.85M

+81.77%

0.062

-141.33%

63.16M

-14.46%

-0.160

+247.6%

Estimates Revision

The market is revising Upward the revenue expectations for Esperion Therapeutics, Inc. (ESPR) for FY2025, with the revenue forecasts being adjusted by 4.16% over the past three months. During the same period, the stock price has changed by 66.43%.

Revenue Estimates for FY2025

Revise Upward

+4.16%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-765%

In Past 3 Month

Stock Price

Go Up

+66.43%

In Past 3 Month

4 Analyst Rating

377.48% Upside

Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is 7.21 USD with a low forecast of 1.85 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

1 Sell

Moderate Buy

377.48% Upside

Current: 1.510

Low

1.85

Averages

7.21

High

16.00

377.48% Upside

Current: 1.510

Low

1.85

Averages

7.21

High

16.00

Goldman Sachs

Paul Choi

Hold

Maintains

$4 → $3

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$4 → $3

2025-04-17

Maintains

Hold

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2025-04-08

Reason

Needham

Serge Belanger

Price Target

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-03-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-03-20

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Jason Butler

Buy

Reiterates

2025-03-05

Reason

Citizens Capital Markets

Jason Butler

Price Target

2025-03-05

Reiterates

Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-03-04

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-03-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-02-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-02-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Esperion Therapeutics Inc (ESPR.O) is -22.21, compared to its 5-year average forward P/E of -3.63. For a more detailed relative valuation and DCF analysis to assess Esperion Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.63

Current PE

-22.21

Overvalued PE

4.58

Undervalued PE

-11.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.01

Current EV/EBITDA

-27.74

Overvalued EV/EBITDA

118.86

Undervalued EV/EBITDA

-100.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.85

Current PS

0.80

Overvalued PS

7.15

Undervalued PS

0.55